体内自由基与Graves病研究新进展

张瑞国; 晋建华

doi:10.3760/cma.j.issn.1673-4114.2009.04.015

体内自由基与Graves病研究新进展

张瑞国 , 晋建华

文章导航 > 国际放射医学核医学杂志 > 2009, 33 > 4: (240-242,248)

引用本文:

Citation:

体内自由基与Graves病研究新进展

张瑞国,
晋建华^,

山西医科大学第一医院核医学科, 太原, 030001

通讯作者: 晋建华, jjhl225@126.com

Study progress on iree radicals and Graves disease

ZHANG Rui-guo,
JIN Jian-hua^,

Department ofNiwkar Medkine, First Hospital of Shanxi Medical University, Taiyuan 030001, China

Corresponding author: JIN Jian-hua, jjhl225@126.com

摘要: 多种疾病的发生、发展与体内自由基介导的氧化损伤密切相关,Graves病时体内也常有活性氧和活性氮等自由基的改变,其氧化应激对甲状腺及人体其他重要脏器都可造成一定的损伤,抗甲状腺药物和¹³¹I治疗Graves病后,机体氧化和抗氧化参数也可发生改变。
- 格雷夫斯病 /
- 自由基 /
- 氧化性应激 /
- 碘放射性同位素
Abstract: Free radical-mediated oxidative injury has been closely implicated in the occurrence and development of many diseases. Graves disease was also accompanied by changes of the free radicals,especially for reactive oxygen species and reactive nitrogen, et al, and the oxidative stress can cause a certain degree of injury on the thyroid and other human important organs. Antithyroid drug and ¹³¹I treatment of Graves disease, the oxidative and antioxidative parameters can also be changed.
- Graves disease /
- Free radicals /
- Oxidative stress /
- Incline radioisotopers
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Sargis RM,Subbaiah PV.Protection of membrane cholesterol by sphingomyelin against free radical-mediated (nidation.Free Radic Biol Med,2006,40(12):2092-2102.
[2]	Stadtman ER,Levine RL Free radical-mediated oxidation of free amino acids and amino acid residues in proteins.Amino Acids,2003,25(3^4):207-218.
[3]	Dizdaroglu M,Jaruga P,Birincioglu M,et al.Free radical-induced damage to DNA:mechanisms and measurement.Free Radic Biol Med,2002,32(11):1102-1115.
[4]	Ademoğlu E,Ozbey N,Erbil Y,et al.Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease.Eur J Intern Med,2006,17(8):545-550.
[5]	Duthoit C,Estienne V,Giraud A,et al.Hydrogen peroxide-induced production of a 40 kDa iramunoreactive thyroglobulin fragment in human thyroid cells:the onset of thyroid autoimmunity?,Biochem J,200U360(pt 3):557-562.
[6]	Komosinska-Vassev K,Olczyk K,Kucharz EJ,et al.Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy.Clin Chim Acta,2000,300(1-2):107-117.
[7]	Bednarek J,Wysocki H,Sowiński J.Oxidative stress peripheral parameters in Graves' disease:the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy.Clin Biochem,2005,38(1):13-18.
[8]	Mayer L,Romić Z,Skreb F,et al.Antioxidants in patients with hyperthyroidism.Clin Chem Lab Med,2004,42(2):154-158.
[9]	Abalovich M,Uesuy S,Gutierrez S,et al.Peripheral parameters of oxidative stress in Graves' disease:the effects of methimazole and 131iodine treatments.Clin Endocrinol,2003,59(3):321-327.
[10]	Fcmdndcz V,Cornejo P,Tapia G, et al.Influence of hyperthyroidism on the activity of liver nitric oxide synthase in the rat.Nitric Oxide,1997,1(6):463-468,
[11]	Colin IM,Kopp P,Zbären J,et al.Expression of nitric oxide synthase III in human thyroid follicular cells:evidence for increased expression in hyperthyroidism.Eur J Endocrinol,1997,136(6):649-655.
[12]	López-Moratalla N,Calleja A,González A,et al.Inducible nitric oxide synthase in monocytes from patients with Graves' disease.Biochem Biophys Res Commun,1996,226(3):723-729.
[13]	Gérard AC,Boucquey M,van den Hove MF,et al.Expression of TPO and ThOXs in human thyrocytes is downregulated by IL-lalpha/IFN-gamma,an effect partially mediated by nitric oxide.Am J Physiol Endocrinol Metab,2006,291(2):242-253.
[14]	Kiotz LO,Schroeder P,Sies H.Peroxynitrite signaling:receptor tyrosine kinases and activation of stress-responsive pathways.Free Hadic Biol Med,2002,33(6):737-743.
[15]	Alturfan AA,Zengin E,Dariyerli N,et al.Investigation of zinc and copper levels in methimazole-induced hypothyroidism:relation with the oxidant-antioxidant status.Folia Biol (Praha),2007,53(5):183-188.
[16]	Hondur A,Konuk O,Dincel AS,et al.Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves' ophthalmopathy. Cuit Eye Res,2008,33(5):421-427,
[17]	Mogulkoc R,Baltaci AK,Oztekin E,et al.Melatonin prevents oxidant damage in various tissues of rats with hyperthyroidism.Life Sci,2006,79(3):311-315.
[18]	Moreno JM,Rodríguez Gómezl,Wangenstcen R,et al.Cardiac and renal antioxidant enzymes and effects of tcmpol in hyperthyroid rats.Am J Physiol Endocrinol Metab,2005,289(5):E776-E783.
[19]	Dani V,Dhawan D.Zinc as an antiperoxidative agent following iodine-131 induced changes on the antioxidant system and on the morphology of red blood cells in rats.Hell J Nucl Med,2006,9(1):22-26.
[20]	Agote Robertson M,Finochietto P,Gamba CA,et al.Nicotinamide increases thyroid radiosensitivity by stimulating nitric oxide synthase expression and the generation of organic peroxides.Horm Metab Res,2006,38(1):12-15.

[1]	张晗玉 , 段炼 . ¹³¹I治疗格雷夫斯病剂量确定方法的探讨. 国际放射医学核医学杂志, 2021, 45(11): 721-727. doi: 10.3760/cma.j.cn121381-202011023-00121
[2]	贺特 , 马云 , 王五洲 , 贺俊彦 , 蒋雨薇 , 曹旭琴 , 何淑雅 . 维生素 E对果蝇辐射氧化损伤机制的影响. 国际放射医学核医学杂志, 2019, 43(3): 257-262. doi: 10.3760/cma.j.issn.1673-4114.2019.03.010
[3]	杨凡慧 , 陈跃 , 张春银 . ¹³¹I治疗青少年及儿童格雷夫斯甲亢的临床应用随访研究. 国际放射医学核医学杂志, 2017, 41(2): 98-102. doi: 10.3760/cma.j.issn.1673-4114.2017.02.004
[4]	管樑 , 陈刚 . 4项甲状腺自身抗体的变化特征及联合半定量评分在格雷夫斯甲亢¹³¹I治疗后疗效的相关性评估中的临床应用价值. 国际放射医学核医学杂志, 2023, 47(12): 746-751. doi: 10.3760/cma.j.cn121381-202209019-00376
[5]	赵炎 , 王俊起 , 沈婕 . Graves病的¹³¹I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析. 国际放射医学核医学杂志, 2017, 41(6): 389-395, 429. doi: 10.3760/cma.j.issn.1673-4114.2017.06.003
[6]	陈栋 , 朱宗平 , 石德道 , 郑飞波 . 阿法骨化醇与¹³¹I治疗Graves病疗效的相关性研究. 国际放射医学核医学杂志, 2020, 44(8): 493-498. doi: 10.3760/cma.j.cn121381-201905011-00065
[7]	胡小春 , 蒋宁一 , 李敬彦 , 张弘 , 刘生 , 卢献平 , 梁九根 , 张占磊 . 硒对经¹³¹I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响. 国际放射医学核医学杂志, 2015, 39(2): 140-143. doi: 10.3760/cma.j.issn.1673-4114.2015.02.008
[8]	牟联超 , 李先映 , 石彩虹 . ¹³¹Ⅰ治疗青少年Graves病58例临床分析. 国际放射医学核医学杂志, 2010, 34(5): 299-301. doi: 10.3760/cma.j.issn.1673-4114.2010.05.013
[9]	孙琦婷 , 赵德善 . Graves病甲状腺功能亢进症与血糖代谢. 国际放射医学核医学杂志, 2010, 34(3): 143-147. doi: 10.3760/cma.j.issn.1673-4114.2010.03.004
[10]	吕进泰 , 尹雅芙 . Graves病¹³¹I治疗的预后因素分析. 国际放射医学核医学杂志, 2019, 43(3): 268-273. doi: 10.3760/cma.j.issn.1673-4114.2019.03.012
[11]	徐海青 , 吴边 . ¹³¹I合并小剂量碳酸锂治疗Graves病的临床探讨. 国际放射医学核医学杂志, 2006, 30(3): 151-152.